Patients with persistently elevated sMICA and TGF-β1 after CRT experienced an earlier tumor progression (mean PFS survival of 7.8 months vs 24.2 months, p = 0.030, Fig 4a), and poor overall survival (mean overall survival of 10.3 months vs 33.8 months, p = 0.010, Fig 4b). Here, TGFB1 is linked to neoplasm.